Ocular Therapeutix OCUL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 87.3%-3.8pp | 91.2%+0.2pp | 91%-0.2pp | 91.2%+1.3pp | |
| Operating margin | -519.8%-250pp | -269.6%-129pp | -141%+11.8pp | -152.7%+26.6pp | |
| Net margin | -511.9%-208pp | -303.7%-166pp | -138.1%-0.2pp | -138%-123pp | |
| EBITDA margin | -511.4%-248pp | -263.6%-128pp | -135.9%+12.8pp | -148.7%+25.1pp | |
| Free cash flow margin | -417.5%-204pp | -213.4%-82.8pp | -130.6%-7.6pp | -123%+30.4pp | |
| Returns | |||||
| Return on equity | -54.9%+40.4pp | -95.2%+32.4pp | -127.6%-12.5pp | -115.2%-107pp | |
| Return on assets | -42%+12.5pp | -54.5%-14.3pp | -40.2%-0.1pp | -40.1%-37.3pp | |
| Efficiency | |||||
| Asset turnover | 0.1×-0.1× | 0.2×-0.1× | 0.3×0.0× | 0.3×+0.1× | |
| Inventory turnover | 2×-0.1× | 2.1×-0.4× | 2.5×-0.3× | 2.8×-0.8× | |
| Liquidity | |||||
| Current ratio | 15.4×+4.7× | 10.7×+4.0× | 6.7×+2.5× | 4.1×-3.1× | |
| Quick ratio | 15.3×+4.7× | 10.6×+4.0× | 6.6×+2.5× | 4.1×-3.2× | |
| Cash ratio | 14.5×+5.0× | 9.5×+3.9× | 5.6×+2.4× | 3.3×-3.0× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×-0.6× | 0.8×-0.2× | 1×+0.6× | |
| Debt-to-assets | 0.1×-0.1× | 0.2×-0.1× | 0.3×+0.1× | 0.2×+0.1× | |
| Interest coverage | -22.8×-10.2× | -12.7×-5.4× | -7.3×+3.9× | -11.2×+0.5× | |
| Per Share | |||||
| Book value per share | $3.49+75.4% | $1.99+87.1% | $1.06+149% | $0.43-60.0% | |
| Valuation | |||||
| Market capitalization | $2.59B+92.6% | $1.34B+257% | $376.56M+74.0% | $216.4M-59.5% | |
| Enterprise value | $1.93B+87.7% | $1.03B+302% | $255M+70.4% | $149.63M-62.8% | |
| Price / sales | 49.8×+28.7× | 21.1×+14.6× | 6.4×+2.2× | 4.2×-8.1× | |
| Price / book | 4×-0.3× | 4.3×+0.1× | 4.1×-2.0× | 6.1×0.0× | |
| EV / sales | 37.1×+21.0× | 16.1×+11.7× | 4.4×+1.5× | 2.9×-6.3× | |
| Free cash flow yield | -8.4%+1.7pp | -10.1%+10.1pp | -20.3%+9.0pp | -29.3%-16.8pp | |
| Earnings yield | -10.3%+4.1pp | -14.4%+7.0pp | -21.4%+11.4pp | -32.8%-31.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ocular Therapeutix's profit margins?
- Ocular Therapeutix (OCUL) runs a 87.2% gross margin and a -575.4% operating margin, with a -558.2% net margin.
- Where do Ocular Therapeutix's ratios come from?
- Every ratio is computed from Ocular Therapeutix's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.